Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOvoca Bio Regulatory News (OVB)

  • There is currently no data for OVB

Schedule 1 - Ovoca Resources

21 Jun 2005 11:18

AIM21 June 2005 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME:Ovoca Resources plc COMPANY ADDRESS:York House, Rear 176 Rathgar Road, Dublin 6, Ireland. COMPANY POSTCODE:N/A COUNTRY OF INCORPORATION:Ireland COMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY:Sourcing and developing exploration assetsOvoca currently has exploration interests in the Former Soviet Union, Sweden andIreland. The Company's Ordinary Shares are traded on the Irish EnterpriseExchange of the Irish Stock Exchange and prior to admission to AIM on a tradingfacility on the SEAQ platform of the London Stock Exchange. DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares,nominal value and issue price to which it seeks admission and the number andtype to be held as treasury shares):Issued Share Capital 110,608,767 Ordinary Shares of €0.025The Company is seeking Admission of the entire issued share capital to AIM. CAPITAL TO BE RAISED ON ADMISSION:N/A FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS:Roger William Turner (Chairman)Dr Barrie William Oakes (Chief Executive Officer)John Durnin O'Connor (Chief Financial Officer)David Harold William Dobson, (Non-Executive Director)Richard Thomas O'Shea (Non-Executive Director)Paul Benedict Smithwick (Non-Executive Director) PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS APERCENTAGE OF THE ISSUED SHARE CAPITAL STATING WHETHER BEFORE OR AFTERADMISSION:Before and after Admission the following are interested in 3% or more: Pershing Nominees International Ltd 7% NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (G) OF THE AIM RULES:Mr. Tom O'Gorman, 8 Hollywood Grove, Newry, Co Down, BT34 1BN, Northern IrelandMr. Hugh Farrington, 15-21 Ushers Quay, Dublin 8, Ireland ANTICIPATED ACCOUNTING REFERENCE DATE:28 February 2005 EXPECTED ADMISSION DATE:30 June 2005 NAME AND ADDRESS OF NOMINATED ADVISER:Davy (J&E Davy), Davy House, 49 Dawson Street, Dublin 2, Ireland NAME AND ADDRESS OF BROKER:Davy (J&E Davy), Davy House, 49 Dawson Street, Dublin 2, Ireland DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BEAVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THEAPPLICANT AND THE ADMISSION OF ITS SECURITIES:The Admission Document will be available to the public on the Company's websitewww.ovoca.ie from the date of this document for a period of at least one monthfrom Admission.The Admission Document will contain full details about the company and the securities subject to Admission DATE OF NOTIFICATION:16 June 2005 NEW/ UPDATE (see note):New QUOTED APPLICANTS MUST ALSO COMPLETE THE FOLLOWING:N/A THE NAME OF THE AIM DESIGNATED MARKET UPON WHICH THE APPLICANT'S SECURITIES HAVE BEEN TRADED: THE DATE FROM WHICH THE APPLICANT'S SECURITIES HAVE BEEN SO TRADED: CONFIRMATION THAT, FOLLOWING DUE AND CAREFUL ENQUIRY, THE APPLICANT HAS ADHEREDTO ANY LEGAL AND REGULATORY REQUIREMENTS INVOLVED IN HAVING ITS SECURITIESTRADED UPON SUCH A MARKET: AN ADDRESS OR WEB-SITE ADDRESS WHERE ANY DOCUMENTS OR ANNOUNCEMENTS WHICH THEAPPLICANT HAS MADE PUBLIC OVER THE LAST TWO YEARS (IN CONSEQUENCE OF HAVING ITSSECURITIES SO TRADED) ARE AVAILABLE: DETAILS OF THE APPLICANT'S STRATEGY FOLLOWING ADMISSION INCLUDING, IN THE CASEOF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY: A DESCRIPTION OF ANY SIGNIFICANT CHANGE IN FINANCIAL OR TRADING POSITION OF THEAPPLICANT, WHICH HAS OCCURRED SINCE THE END OF THE LAST FINANCIAL PERIOD FORWHICH AUDITED STATEMENTS HAVE BEEN PUBLISHED: A STATEMENT THAT THE DIRECTORS OF THE APPLICANT HAVE NO REASON TO BELIEVE THATTHE WORKING CAPITAL AVAILIABLE TO IT OF ITS GROUP WILL BE INSUFFICIENT FOR ATLEAST TWELVE MONTHS FROM THE DATE OF ITS ADMISSION: DETAILS OF ANY LOCK-IN ARRANGEMENTS PURSUANT TO RULE 7 OF THE AIM RULES: A BRIEF DESCRIPTION OF THE ARRANGEMENTS FOR SETTLING THE APPLICANT'S SECURITIES: A WEBSITE ADDRESS DETAILING THE RIGHTS ATTACHING TO THE APPLICANT'S SECURITIES: INFORMATION EQUIVALENT TO THAT REQUIRED FOR AN ADMISSION DOCUMENT WHICH IS NOT CURRENTLY PUBLIC: A WEBSITE ADDRESS OF A PAGE CONTAINING THE APPLICANT'S LATEST ANNUAL REPORT ANDACCOUNTS WHICH MUST HAVE A FINANCIAL YEAR END NOT MORE THEN NINE MONTHS PRIOR TOADMISSION AND FULLY AUDITED INTERIM RESULTS WHERE APPLICABLE. THE ACCOUNTS MUSTBE PREPARED ACCORDING TO UK OR US GAAP OR INTERNATIONAL ACCOUNTING STANDARDS. THE NUMBER OF EACH CLASS OF SECURITIES HELD IN TRESURY. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Jul 20227:00 amRNSCompletion of Enrollment in Phase II Study
30th Jun 20227:00 amRNSAnnual Financial Report
7th Mar 20229:00 amRNSStatement re Russian Business Operations
23rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
23rd Feb 20224:36 pmRNSPrice Monitoring Extension
22nd Feb 20223:30 pmRNSRussian Marketing Authorisation for Orenetide
31st Jan 20227:00 amRNSBoard Changes and Update
30th Dec 20217:00 amRNSDirectorate Change
4th Nov 20213:53 pmRNSHolding(s) in Company
4th Nov 20213:50 pmRNSDirector/PDMR Shareholding
4th Nov 20213:46 pmRNSBoard Change
14th Sep 20217:00 amRNSInterim Results
29th Jul 20215:00 pmRNSResult of AGM
24th Jun 20217:00 amRNSAnnual Report and Notice of AGM
10th Mar 20217:00 amRNSMigration of Participating Securities
16th Feb 20212:00 pmRNSResult of EGM
29th Jan 20217:00 amRNSFirst Patient Enrolled in Phase II Study - BP-101
25th Jan 20213:30 pmRNSNotice of EGM
5th Jan 20217:00 amRNSRe-Filing of Marketing Authorisation Application
17th Dec 20202:45 pmRNSResult of AGM
27th Nov 20203:08 pmRNSNotice of AGM
9th Oct 20207:00 amRNSAppointment of Chief Business Officer
2nd Oct 202011:06 amRNSSecond Price Monitoring Extn
2nd Oct 202011:00 amRNSPrice Monitoring Extension
2nd Oct 20209:05 amRNSSecond Price Monitoring Extn
2nd Oct 20209:00 amRNSPrice Monitoring Extension
2nd Oct 20207:00 amRNSUpdate re Russian Marketing Authorisation
28th Sep 20207:00 amRNSDeath of a Director
21st Sep 20207:00 amRNSInterim Results
14th Aug 202011:05 amRNSSecond Price Monitoring Extn
14th Aug 202011:00 amRNSPrice Monitoring Extension
26th Jun 20207:00 amRNSAnnual Report
14th Apr 20202:05 pmRNSSecond Price Monitoring Extn
14th Apr 20202:00 pmRNSPrice Monitoring Extension
24th Mar 20207:00 amRNSAcquisition of Remaining Minority Interest in IVIX
7th Nov 201912:45 pmRNSAttendance at Bio-Europe Conference
16th Sep 20197:00 amRNSInterim Results
12th Sep 20197:00 amRNSFiling of Marketing Authorisation Application
28th Aug 20197:00 amRNSDirectorate Change
8th Aug 20194:14 pmRNSResult of AGM
8th Aug 20199:05 amRNSSecond Price Monitoring Extn
8th Aug 20199:00 amRNSPrice Monitoring Extension
8th Aug 20197:00 amRNSAGM Statement
26th Jul 20197:00 amRNSDirectorate Change
25th Jul 20194:41 pmRNSSecond Price Monitoring Extn
25th Jul 20194:35 pmRNSPrice Monitoring Extension
28th Jun 20197:00 amRNSAnnual Report and Notice of AGM
23rd Apr 20197:00 amRNSUS and EU Clinical Development Plans
29th Mar 20197:00 amRNSDirector/PDMR Shareholding
27th Mar 20197:00 amRNSOperational Update & Additional Investment in IVIX

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.